

JIM 04578

## Preparation and characterization of monoclonal antibodies against the fifth component of rabbit complement (C5) \*

P.C. Giclas<sup>1,2</sup>, S.L. Baker<sup>1</sup>, M.L. Gillespie<sup>1</sup> and C. Wilcox<sup>1</sup>

<sup>1</sup> Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine,  
and <sup>2</sup> Department of Medicine, Pulmonary Division, UCHSC, Denver, CO, U.S.A.

(Received 6 June 1986, revised received 20 July 1987, accepted 28 July 1987)

By immunizing mice genetically deficient in C5 we were able to obtain a group of monoclonal antibodies to rabbit C5 that cross-react with C5 from a wide variety of mammalian sera, including mouse. The specificity of the monoclonal antibodies was against native C5 and C5b but not C5a. The antibodies strongly inhibit the expression of C5 hemolytic activity. We suggest that these monoclonal antibodies will be useful for studying C5 as well as providing a way to selectively deplete C5 from plasma in vitro or in vivo.

**Key words:** C5; Monoclonal antibody; Complement, rabbit

### Introduction

The fifth component of the complement system (C5) is a plasma glycoprotein that is converted to its biologically active forms when cleaved by C5 convertases of the alternative or classical pathway, or by other serine proteases present in injured tissues (Cooper and Müller-Eberhard, 1970; Arroyave and Müller-Eberhard, 1973; Hugli, 1977; Discipio et al., 1981; Wiggins et al., 1981; Sundsmo and Fair, 1985). The fragments, C5a and C5b, are responsible for inducing neutrophil chemotaxis, enhancing the phagocytic, oxygen radical and enzymatic responsiveness of inflammatory cells, and participating in killing through complement membranolytic mechanisms (Cochrane and Müller-Eberhard, 1968; Bhakdi and Tranum-Jensen, 1978; Hugli, 1981; Bult and Herman, 1983). Limited

digestion of the molecule with non-complement enzymes can produce two fragments of the  $\alpha$ -chain that remain attached to the  $\beta$ -chain by disulfide bonds, giving a molecule with unaltered molecular weight or charge, but with the C5a-like ability to attract neutrophils and C5b-like ability to form a stable complex with C6 (Wetsel and Kolb, 1983).

Individuals who lack C5 are susceptible to recurrent severe bacterial infections (Alper and Rosen, 1984). Larsen and his co-workers showed that C5-deficient mice had lowered survival and recovery when infected with *Pseudomonas aeruginosa*. By contrast, C5-sufficient mice were less hardy than were C5-deficient mice when maintained in hyperoxic conditions, suggesting that C5 contributes to the pulmonary inflammation that occurs during hyperoxia (Larsen et al., 1982; Parrish et al., 1984). Further definition of the role of C5a during inflammation has been hampered by the lack of appropriate reagents for detecting C5 and its activation products in vivo in diverse animal species. In the present paper, we report the development of mouse monoclonal anti-rabbit

Correspondence to: P.C. Giclas, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, 1400 Jackson Street, Denver, CO 80206, U.S.A.

\* Supported in part by NIH Grants AI-17286 and HL-27353.

C5 antibodies that cross-react strongly with C5 from a wide variety of mammalian sera. The four antibodies that are described are directed against native C5 and C5b, but not C5a, and have been used to form immunoaffinity beads to study C5 obtained from plasma.

## Materials and methods

Immunization of mice, hybridoma production, and ascites collection: four C5-deficient mice (B10.D2/oSn) were immunized because it was hoped that they would respond to rabbit C5 with a broader variety of antibodies than C5-sufficient mice. Each mouse was given 0.1 ml sterile saline containing 52  $\mu$ g of purified rabbit C5 (Giclas et al., 1981a) intravenously, followed by booster intraperitoneal injections of the same amount of C5 at 1 week, and intravenous injections at 3 and 4 weeks. 4 days after the last injection, the mice were test bled and all four test sera gave single immunoprecipitin lines showing identity with C5 precipitated from rabbit serum by goat anti-rabbit C5. The mice were killed and their spleen cells isolated and fused with P3x63Ag8 mouse myeloma cells to form hybridomas, using the method of Köhler et al. (1975) to isolate cells insensitive to hypoxanthine, aminopterin and thymidine. Successful hybridomas were grown in 96-well tissue culture plates at a starting cell density of  $1.5 \times 10^5$  cells/well, and cloned by limiting dilution transfer, adding mouse peritoneal cells from a non-immunized animal as feeder cells to promote growth.

An ELISA was used to screen the initial spleen cell colonies and subsequent subclones for antibodies to rabbit C5. The antigen source employed by this assay was either normal rabbit serum (NRS), zymosan-activated rabbit serum (ZARS) containing C5 breakdown products, a 6–11% polyethylene glycol (PEG-4000) cut of NRS that was enriched for C5 concentration, or a mixture of rabbit C3 and C5 obtained as by-products of C5 purification. All the above were diluted in carbonate buffer, pH 9.5, so they contained between 0.8 and 1.0  $\mu$ g/ml of C5. Rabbit serum albumin (RSA) was used as negative control for the antigens, and an unrelated monoclonal antibody (PLD1), against a rabbit platelet surface

antigen, was used as a control antibody. The antigen (100  $\mu$ l/well) was placed in 96-well microtiter plates (Falcon Microtest III), incubated overnight in a humidified chamber at 4°C, and washed three times with phosphate-buffered saline, pH 7.4, containing 0.05% Tween 20 (PBS-Tween). Buffer containing 2% bovine serum albumin (PBS-BSA) was added to each well and incubated at room temperature for 1 h to block remaining binding sites. The plates were again washed three times with PBS-Tween. Hybridoma supernatants were added to the wells, either undiluted or serially diluted in PBS-Tween, incubated for 1 h at 37°C, and washed three times with PBS-Tween. Alkaline phosphatase-conjugated rabbit anti-mouse IgG (H and L) was added and incubated for 1 h at room temperature, followed by washing three times with PBS-Tween. *p*-Nitrophenyl phosphate, a chromogenic substrate for alkaline phosphatase, was then added, the plate incubated for 1 h at room temperature, and the optical density at 405 nm determined by an ELISA reader (BioTek Instruments, Burlington, VT). Alkaline phosphatase and its substrate were purchased from Bio-Rad (Richmond, CA).

The IgG fraction from the ascites fluid was purified by precipitation with an equal volume of ice-cold saturated ammonium sulfate (SAS). The precipitate was washed in 50% SAS in the cold, and redissolved in a small volume of distilled water. This solution was dialyzed overnight against 20 vols. of 0.01 M phosphate buffer, pH 8.1, and applied to a DEAE-cellulose column (Whatman DE52) previously equilibrated with the same buffer. The column was washed with the starting buffer and the flow-through peak collected. The remaining bound protein was eluted from the column with a linear gradient to 0.5 M NaCl, and fractions were assayed for IgG by immunodiffusion against rabbit anti-mouse IgG (H and L), and for specific antibody by ELISA.

SDS-PAGE analysis employed 7.5% T, 2% C slab gels run under reducing conditions (Laemmli, 1970) and stained with silver stain (Tsang et al., 1984) unless otherwise indicated. Reagents for the polyacrylamide gels were purchased from Bio-Rad (Richmond, CA). Rocket immunoelectrophoresis and immunodiffusion were done by standard methods (Laurell, 1966), using 1% agarose

(Seakem, ME, FMC, Rockland, ME). C5 were obtained (Scarborough, ME) anti-rabbit C5 was (Giclas et al., 1981).

Radioiodination with  $^{125}$ I (New England Nuclear, Boston, MA) was catalyzed by Iodogen (New England Nuclear, Rockford, IL), and by a small column (Bio-Rad, Richmond, CA) as described (Giclas et al., 1984). Typical specific activities were 1.5  $\times 10^6$  dpm/nmol, and than 95% of the radioactivity was trichloroacetic acid precipitable.

Immunoaffinity chromatography: pling the IgG fraction with antibodies to cyanogen bromide-activated CL6B (Pharmacia, Lincoln, NE) pling efficiency for 60–65% of the protein. mg IgG/ml of beads.

Rabbit, rat, C5 mouse, guinea pig animals housed at the University of Colorado. Ferret serum was a gift from Dr. Irvin, snake (*Pituophis elegans*) serum from Dr. Cohen and John C. and horse sera were from Dr. Denver, CO. Albacore sheep sera were obtained from a body production at the University of Colorado.

Rabbit C5 was purified by electrophoresis or concentration, and her activity (Giclas et al., 1984) pool of NRS was used. C5 fragments were purified by ion exchange of NRS with 2% acetic acid (mg/ml) or cobra venom.

## Results

Four clones were obtained from ascites fluid in BALB/c mice.

(Seakem, ME, FMC Marine Biologicals Division, Rockland, ME). Anti-human C3 and anti-human C5 were obtained from Atlantic Antibodies (Scarborough, ME) and goat anti-rabbit C3 and anti-rabbit C5 were prepared in our laboratory (Giclas et al., 1981a).

Radioiodination of the monoclonal antibodies with  $^{125}\text{I}$  (New England Nuclear, Boston, MA) was catalyzed by Iodogen (Pierce Chemical Co., Rockford, IL), and unbound iodine was removed by a small column of AG-1X8 (Bio-Rad, Richmond, CA) as described elsewhere (Manthei et al., 1984). Typical specific activities achieved by this method were  $1.5 \mu\text{Ci}/\mu\text{g}$  protein, with greater than 95% of the radioactivity precipitable by 10% trichloroacetic acid.

Immunoaffinity beads were prepared by coupling the IgG fraction of one of the monoclonal antibodies to cyanogen bromide-activated Sepharose-CL6B (Pharmacia, Upsala, Sweden). Coupling efficiency for the IgG fractions was typically 60–65% of the protein, giving approximately 12–20 mg IgG/ml of beads.

Rabbit, rat, C5-sufficient mouse, C5-deficient mouse, guinea pig, and hamster sera were from animals housed at the investigator's institution. Ferret serum was a generous gift from Dr. Charles Irvin, snake (*Pituophis melanoleucus* and *Thamnophis elegans*) sera were given by Drs. Robert R. Cohen and John Caldwell, and chicken, monkey, and horse sera were from Christina Stevens, all of Denver, CO. Albacore serum was left over from a previous study (Giclas et al., 1981b), and goat and sheep sera were obtained as by-products of antibody production and sheep red blood cell collection.

Rabbit C5 was assayed by rocket immunoelectrophoresis or ELISA to determine its concentration, and hemolytic assays to determine its activity (Giclas et al., 1981a, 1985). A standard pool of NRS was used to calibrate all C5 assays. C5 fragments were generated in vitro by incubation of NRS with zymosan (4 mg/ml), inulin (10 mg/ml) or cobra venom factor (4 U/ml).

## Results

Four clones were chosen for production of ascites fluid in BALB/C  $\times$  B10.D2/oSn  $F_1$  mice.

Hybrid mice were used because the hybridomas were derived by fusion of cells from both strains. Ascites fluids were collected and pooled, and the IgG fractions isolated.

An ELISA titration was done with the first monoclonal antibody (CWD1) against NRS, PEG-RS, C3/C5 and RSA, diluted so that the C5 concentration in each of the first three was 0.8–1.0  $\mu\text{g}/\text{ml}$ , and the RSA concentration was the same as that in diluted NRS. Equivalent binding was obtained to all of the C5-containing antigen sources (Fig. 1) and no binding to RSA occurred. Similar results were obtained with the other three monoclonal antibodies. Table I lists results from two sets of experiments that were done as follows: (1) ELISA titration was performed, using C3/C5 as the antigen source, and the monoclonal anti-C5 antibodies and the unrelated monoclonal antibody (PLD1) were compared for their binding capacities. The results were calculated as the log of the antibody concentration (ng/ml) versus the percent of maximum color development in the ELISA, and the curves analyzed by linear regression to obtain the concentration at which 50% of the




Fig. 1. ELISA titration of CWD1 monoclonal anti-rabbit C5 ascites fluid against NRS (■), PEG-RS (●), C3/C5<sup>rab</sup> (▲) and RSA (○), as described in the text. C5 concentrations of the first three antigens were 0.8–1.0  $\mu\text{g}/\text{ml}$ , and CWD1 ascites protein concentration was 70 mg/ml.

TABLE I

AMOUNT OF MONOCLONAL ANTIBODY (PURIFIED IgG) NEEDED TO ACHIEVE 50% OF MAXIMUM RESPONSE IN ELISA, OR 50% INHIBITION OF HEMOLYTIC C5 ACTIVITY

Antibody used	IgG concentration (ng/ml)	
	ELISA	C5H50
CWD1	110.3 ± 14.5 (7:1) <sup>a</sup>	560 ± 75 (1:6.2)
CWD2	20.9 ± 0.8 (38:1)	333 ± 76 (1:3.7)
CWD3	13.8 ± 0.6 (58:1)	50 ± 13 (1:0.6)
CWD4	20.3 ± 1.2 (39:1)	907 ± 154 (1:10.1)
PLD1	<sup>b</sup>	1.08 × 10 <sup>8</sup> (1:1.2 × 10 <sup>6</sup> )

<sup>a</sup> Mean ± SD (antigen: antibody ratio, w/w)

<sup>b</sup> PLD1 was less than or equal to background with no antibody.

maximum response occurred. (2) Inhibition of C5 hemolytic activity was measured in samples of the NRS pool diluted 1:1000 in buffer containing 0.01 M EDTA, giving approximately 80 ng/ml C5. EDTA does not inhibit the assay for C5, but was used to block possible activation of complement by C5-anti-C5 immune complexes. The NRS-EDTA dilutions were preincubated for 30 min at 37°C with serial dilutions of each of the anti-C5 monoclonals and PLD1, and C5 titers were determined by hemolytic assays. CWD3 showed the greatest inhibition of C5 hemolytic activity per ng of IgG, and also had the highest titer in the ELISA.

In order to determine whether any of the four antibodies reacted with the C5a fragment of rabbit C5, a preparation of rabbit C5 fragments (C5f) was prepared from zymosan-activated rabbit plasma by the method of Fernandez and Hugli (1976), with substitution of molecular sieving through a membrane with a nominal  $M_r$  30 000 cut-off (Centricon-30, Amicon, Lexington, MA) for the gel filtration column. The resulting rabbit C5f preparations had specific activities equivalent to highly purified human C5a, when tested for their ability to induce enzyme release from cytochalasin B-treated human neutrophils (Webster et al., 1980), and to induce vascular hyperpermeability in rabbit skin (Cochrane and Müller-Eberhard, 1968). Because it was likely that the ascites fluid contained carboxypeptidase N activity that might inactivate the C5f (Vallota and Müller-Eberhard,

1973), the antibodies to be used were pretreated with the arginine analogue, MGETPA, (DL-2 mercaptomethyl-3-guanidinoethyl-thiopropionic acid, Calbiochem, La Jolla, CA), a competitive carboxypeptidase inhibitor (Plummer and Ryan, 1981). Aliquots of the C5f preparation were incubated for 30 min at room temperature with buffer or with dilutions of the MGETPA-treated CWD antibodies, and then assayed for their ability to induce myeloperoxidase release from human neutrophils (Webster et al., 1980). Table II gives data from an experiment in which there was no significant difference from the activity of C5f when incubated with CWD1, PLD1, or no antibody. None of the monoclonal antibodies had anti-C5a activity when tested by this method. In another set of experiments, the rabbit C5f preparation was incubated with immunoaffinity beads containing either the monoclonals, anti-human C3 or anti-human C5 for 30 min at room temperature in buffer containing 1 M MGETPA. The immunoaffinity beads were then removed from the C5f by centrifugation, and remaining activity assayed as above. There was no decrease in the MPO titer of the C5f after treatment with any of the immunoaffinity beads.

Since none of the monoclonal antibodies formed precipitin lines on immunodiffusion against rabbit serum, each was radiolabelled with <sup>125</sup>I and mixed with a 'carrier' antiserum (goat anti-human C5, or anti-whole rabbit serum) so that each mixture contained approximately 1 × 10<sup>5</sup> cpm/μl. Results of immunoelectrophoresis of NRS and ZARS are shown in Fig. 2. As can be seen from the auto-

TABLE II

SECRETOGOGUE ACTIVITY OF RABBIT C5f AFTER INCUBATION WITH MONOCLONAL ANTI-C5, OR PLD1, AN UNRELATED MONOCLONAL

Antibody dilution	Enzyme release <sup>a</sup>	
	CWD1	PLD1
1/10	16.5 ± 9.5	51.7 ± 18.9
1/100	87.8 ± 14.3	114.3 ± 13.6
1/1000	101.2 ± 26.8	109.0 ± 1.6
1/10000	93.3 ± 7.2	128.7 ± 27.2

<sup>a</sup> Percent of maximum release induced by C5f (35% of total MPO in neutrophils) (mean ± SD, n = 3).




Fig. 2. A: Immunoelectrophoresis of NRS and ZARS. Wells marked N contained rabbit serum, and wells marked Z contained rabbit serum mixed with 1-4 contained goat anti-human C5, or anti-whole rabbit serum, or -3, or -4, respectively. B: Immunoelectrophoresis of NRS and ZARS. Wells marked N contained rabbit serum, and wells marked Z contained rabbit serum mixed with 1-4 contained goat anti-human C5, or anti-whole rabbit serum, or -3, or -4, respectively.

radiograms, all formed a single arc. Only one arc, corresponding to the C5f, was radiolabelled. CWD4 was used. CWD4 was used in the last trough, and no arc was visible. In parallel experiments, C5f was mixed with anti-C3, anti-C4, or anti-C5. CWD antibodies did not form arcs except anti-C5.

A further experiment was performed with the CWD antibodies. Rabbit C5f was mixed with immunoaffinity beads containing anti-C3, anti-C4, anti-C5, or anti-human C5. CWD antibodies did not form arcs except anti-C5.




Fig. 2. A: Immunoelectrophoresis gel stained with 1% amido black. Wells marked N contained normal rabbit serum, those marked Z contained zymosan-activated rabbit serum. Troughs 1-4 contained goat anti-rabbit C5 mixed with  $^{125}$ I-CWD1, -2, -3, or -4, respectively, and trough 5 contained an equal amount of  $^{125}$ I-CWD4 mixed with anti-rabbit serum albumin. B: Autoradiogram of the same gel.

radiograms, all four CWD antibodies coprecipitated with the anti-C5 against both C5 and C5b. Only one arc, corresponding to the position of C5, was radiolabelled when anti-whole rabbit serum was used. CWD4 was mixed with anti-RSA in the last trough, and no radiolabel was coprecipitated. In parallel experiments, each of the monoclonals was mixed with a variety of antisera, including anti-C3, anti-C4, and anti-IgG, but none of the CWD antibodies coprecipitated with any antibody except anti-C5.

A further experiment was done to verify that the CWD antibodies were specific for C5. Immunoaffinity beads were prepared with each monoclonal, and with polyclonal anti-human C3 and anti-human C5. A small aliquot of each of

these affinity beads was incubated with NRS in the presence of 0.01 M EDTA, and washed exhaustively with 0.02 M Tris pH 7.4, containing 0.15 M NaCl and 0.1% Tween 20 to remove non-specifically bound protein. The beads were then washed with 3.8% sodium thiocyanate to elute the bound antigen, and this was reduced and analyzed by SDS-PAGE. The gels were silver stained and scanned by a soft laser 2D scanning densitometer (Biomed Instruments, Livermore, CA). The first gel was run with samples precipitated by the four monoclonals along with anti-human C3 immunoaffinity beads. The superimposed tracings shown in Fig. 3A were from protein eluted from CWD3 and anti-C3, and it can be seen that the  $\alpha$  chains were different. The superimposed tracings shown in Fig. 3B were from protein eluted from CWD3 and anti-C5. The molecular weights of the proteins eluted from all four CWD antibodies were the same as C5  $\alpha$  and  $\beta$  chains, and were different from C3. The lower bands on the gel are albumin (67 kDa) and the heavy chain of mouse IgG (50 kDa), both of which were contaminants on all of the gels. Preadsorption of the NRS sample by beads containing goat anti-C5 depleted the protein bound by the CWD beads but preadsorption with anti-C3 beads did not. Further proof that the antigen was C5 was obtained from the gel shown in Fig. 4, in which normal and C5-deficient human sera and mouse sera were precipitated with the immunoaffinity beads. The anti-C3 immunoaffinity beads brought down two-chain C3 protein from all four sera, whereas the CWD4 immunoaffinity beads brought down two-chain C5 protein only from the two normal sera and not from the C5-deficient sera.

To determine the cross-reactivity of the monoclonals with C5 of different species, sera were obtained from the following animals: rabbit, rat, guinea pig, hamster, mouse, dog, cat, ferret, monkey, human, goat, horse, cow, sheep, tuna, bull snake, garter snake, and chicken. Immunoprecipitates were made from each of these with the immunoaffinity beads, and analyzed on silver-stained polyacrylamide gels. The proteins precipitated from all of the mammalian sera had two chains with molecular weights similar to those of rabbit C5. Fig. 5 shows a gel that was scanned and the molecular weights of the  $\alpha$  and  $\beta$  chains




Fig. 3. A: Scanning densitometer tracing of a polyacrylamide gel lane containing protein immunoprecipitated from normal rabbit serum using immunoaffinity beads with goat anti-human C3 (solid line) superimposed on tracing from the adjacent lane containing protein immunoprecipitated with CWD3, as described in the text. Positions of the C3 and C5  $\alpha$  and  $\beta$  chains are shown on the bottom, along with molecular weight marker positions. B: Densitometric tracing of lanes containing proteins precipitated from rabbit serum by anti-human C5 (solid line) or CWD3.

were as follows: human = 113 720 and 76 049, ferret = 113 111 and 75 641, dog = 119 631 and 82 427, rabbit = 117 089 and 77 284, mouse = 113 415 and 83 317, hamster = 113 835 and 86 074, rat = 118 353 and 81 986, guinea pig = 115 102 and




Fig. 4. Polyacrylamide gel analysis of normal and C5-deficient mouse serum (N and D) and normal and C5-deficient human serum (N and D), immunoprecipitated with immunoaffinity beads containing CWD4 monoclonal anti-rabbit C5. Positions of molecular weight standards are shown at right. The protein at  $M_r$  67 000 in all four lanes is albumin, a frequent contaminant of the immunoprecipitates. The protein at  $M_r$  80 000 in the lanes from the two human sera has not been identified, but was also present in lanes from control immunoaffinity beads with anti-C3.

83 261. The albacore, snake, and chicken sera did not produce two distinct chains, but had broad bands at approximately 70–80 000. Whether these are related to C5 has not been ascertained.

Experiments to define the binding site of the monoclonals indicate that it is present only on undenatured, non-reduced C5 or C5b. This is demonstrated in Fig. 6. Aliquots of NRS were incubated with the complement activators zymosan, inulin, and cobra venom factor, then immunoprecipitated and examined by SDS-PAGE. However, if the antigen was denatured or reduced on SDS-polyacrylamide gels and Western blot analysis done with the monoclonal antibodies, no specific binding could be detected. Purified rabbit C5 was treated with 0.2 M mercaptoethanol (1 h, room temperature) followed by alkylation with 0.3 M Iodoacetic (pH 7.5, 1 h on ice). The reduced and alkylated protein was incubated with immunoaffinity beads as above, and the bound pro-

Fig. 5. Polyacrylamide gel analysis of rabbit (D) and mouse (E) sera. Each lane, as well as the

tein analyzed on polyacrylamide gel containing reduced and alkylated C5. Two bands at the C5  $\alpha$  and C5  $\beta$  positions were seen in lanes containing immunoaffinity beads, but not in lanes of those from CWD3 in the C5  $\beta$  position.

## Discussion

Four monoclonal antibodies were raised against rabbit C5. The specificity of the antigen was confirmed by Western blotting with labelled monoclonal antibodies and antisera against






Fig. 5. Polyacrylamide gel showing proteins immunoprecipitated from sera of nine animals species: (A) human, (B) ferret, (C) dog, (D) rabbit, (E) mouse, (F) hamster, (G) rat, (H) guinea pig, and (I) albacore (left to right). Albumin can be seen below the  $\beta$  chains in each lane, as well. The approximate positions of C5  $\alpha$  and C5  $\beta$  are marked on the right side, and the molecular weight standards are shown at left.

tein analyzed on polyacrylamide gels. The gel lane containing reduced and alkylated C5 control had two bands at the C5  $\alpha$  and C5  $\beta$  positions, but the lanes containing protein eluted from the immunoaffinity beads were blank, with the exception of those from CWD4 that had faint protein bands in the C5  $\beta$  position.

## Discussion

Four monoclonal antibodies that were prepared against rabbit C5 have been described. The identity of the antigen recognized by these antibodies was confirmed by several means. First, radio-labelled monoclonal antibodies coprecipitated only with antisera against rabbit or human C5, and not

with antisera against C3, C4, albumin, or any other plasma proteins. Second, the protein immunoprecipitated from rabbit serum with immobilized monoclonal antibodies consisted of two polypeptide chains with the same molecular weights as those of C5, and was clearly different from C3. Third, no protein could be precipitated from C5-deficient human or mouse sera, whereas C3 was precipitable from both normal and C5-deficient sera with anti-human C3 immunoaffinity beads. Fourth, the monoclonals all recognized both native C5 and C5b, but not C5a.

Our original idea that the C5-deficient mouse was immunologically naive to C5 and therefore more likely to make antibodies with fewer species-restricted specificities was borne out. Broad cross-reactivity was shown by the ability of the




Fig. 6. Polyacrylamide gel analysis of C5 protein precipitated from rabbit serum at time 0, 5, and 30 min after initiation of complement activation with inulin (10 mg/ml), zymosan (4 mg/ml) and cobra venom factor (4 U/ml). The appearance of the C5  $\alpha'$  chain ( $104,136 \pm 436$  Da) can be seen at 5 and 30 min.

monoclonals to precipitate C5 from the sera of a wide variety of mammalian species, but not from sera of the non-mammalian vertebrates tested to date, suggesting that they recognize relatively well conserved configurations of C5. The exact binding sites of the monoclonals have not yet been determined. They all bound C5 from normal serum and C5b from activated serum. Attempts to probe Western blots of reduced C5 with  $^{125}\text{I}$ -CWD antibodies were negative, and when purified C5 was reduced and alkylated in solution, the immunoaffinity beads were no longer able to precipitate protein. Thus, the conformational changes that accompany denaturation appear to make the binding site unavailable.

Because these monoclonal antibodies react with C5 from many different species, they should pro-

vide useful tools for studying C5 activation in vivo and in vitro, as well as providing a way to selectively deplete animal sera of C5 and thus create homologous assay systems for measuring C5 hemolytic activity in these species, or, using F(ab') fragments, to temporarily deplete C5 in vivo.

## References

- Alper, C.A. and Rosen, F.S. (1985) Inherited deficiencies of complement proteins in man. In: H.J. Müller-Eberhard and P.A. Miescher (Eds.), *Complement*. Springer-Verlag, Berlin, p. 409.
- Arroyave, C.M. and Müller-Eberhard, H.J. (1973) Interactions between human C5, C6, and C7, and their functional significance in complement-independent cytotoxicity. *J. Immunol.* 111, 536.

- Ballou, M. and Coombs, R. (1966) Factors in the lysis of erythrocytes by cobra venom factor. *J. Biol. Chem.* 241, 5655.
- Bult, H. and Hermans, J. (1975) Complement released by cobra venom factor. *Immunology* 13, 405.
- Cochrane, C.G. and Coombs, R. (1966) Isolation of two distinct components of cobra venom factor and their fifth component. *Immunology* 127, 371.
- Cooper, N.R. and Müller-Eberhard, H.J. (1975) Mechanism of human C5 activation. *Med.* 132, 775.
- DiScipio, R.G. (1981) Isolation of the C5 component C5 in the alternative pathway C5 convertase. *Immunology* 127, 371.
- Fernandez, H.N. and Coombs, R. (1966) Isolation of human C5 and its activation by cobra venom factor. *Immunology* 127, 371.
- Giclas, P.C., Keeling, J.P., and Keeling, J.P. (1981) Characterization of rabbit complement component C5. *Immunology* 127, 371.
- Giclas, P.C., Morris, J., and Ulevitch, R.J. (1975) Isolation of cobra venom factor (CVF) from cobra venom. *Thromb. Haemostas.* 437.
- Hugli, T.E. (1977) Complement activation. In: *Effects of thrombin on blood coagulation*. Lundblad, J.W. Ed. Ann Arbor, MI, p. 1.
- Hugli, T.E. (1981) The chemotactic function of complement. *Rev. Immunol.* 2, 1.
- Köhler, G., Howe, S., and Millican, M. (1975) Cultures of fused cells: specificity. *Nature* 258, 680.
- Laemmli, U.K. (1970) The assembly of the complement. *Nature* 227, 680.



- Ballow, M. and Cochrane, C.G. (1969) Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. *J. Immunol.* 103, 944.
- Bhakdi, S. and Trantum-Jensen, J. (1978) Molecular nature of the complement lesion. *Proc. Natl. Acad. Sci. U.S.A.* 75, 5655.
- Bult, H. and Herman, A.G. (1983) Inflammatory mediators released by complement-derived peptides. *Agents Actions* 13, 405.
- Cochrane, C.G. and Müller-Eberhard, H.J. (1968) The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. *J. Exp. Med.* 127, 371.
- Cooper, N.R. and Müller-Eberhard, H.J. (1970) The reaction mechanism of human C5 in immune hemolysis. *J. Exp. Med.* 132, 775.
- DiScipio, R.G. (1981) The conversion of human complement component C5 into fragment C5b by the alternative pathway C5 convertase. *Biochem. J.* 199, 497.
- Fernandez, H.N. and Hugli, T.E. (1976) Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide portions of human C5a. *J. Immunol.* 117, 1688.
- Giclas, P.C., Keeling, P.J. and Henson, P.M. (1981a) Isolation and characterization of the third and fifth components of rabbit complement. *Mol. Immunol.* 18, 113.
- Giclas, P.C., Morrison, D.C., Curry, B.J., Laurs, R.M. and Ulevitch, R.J. (1981b) The complement system of the albacore tuna, *Thunnus alalunga*. *Dev. Comp. Immunol.* 5, 437.
- Hugli, T.E. (1977) Complement factors and inflammation: Effects of thrombin on components C3 and C5. In: R.L. Lundblad, J.W. Fenton and K.G. Mann (Eds.), *Chemistry and Biology of Thrombin*. Ann Arbor Science Publishers, Ann Arbor, MI, p. 345.
- Hugli, T.E. (1981) The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. *CRC Crit. Rev. Immunol.* 2, 321.
- Köhler, G., Howe, S.C. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256, 495.
- Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T<sub>4</sub>. *Nature* 227, 680.
- Larsen, G.L., Mitchell, B.C., Harper, T.B. and Henson, P.M. (1982) The pulmonary response of C5 sufficient and deficient mice to *Pseudomonas aeruginosa*. *Am. Rev. Resp. Dis.* 126, 306.
- Laurell, C.B. (1966) Quantitative estimation of proteins by electrophoresis into agar containing antibodies. *Anal. Biochem.* 15, 45.
- Manthei, U., Strunk, R.C. and Giclas, P.C. (1984) Acute local inflammation alters synthesis, distribution, and catabolism of the third component of complement (C3) in rabbits. *J. Clin. Invest.* 74, 424.
- Parrish, D.A., Mitchell, B.C., Henson, P.M. and Larsen, G.L. (1984) The pulmonary response of C5 sufficient and deficient mice to hyperoxia. *J. Clin. Invest.* 7, 956.
- Plummer, T.H. and Ryan, T.J. (1981) A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. *Biochem. Biophys. Res. Commun.* 98, 448.
- Sundsmo, J.S. and Fair, D.S. (1985) Relationships among the complement, kinin, coagulation, and fibrinolytic systems. In: H.J. Müller-Eberhard and P.A. Miescher (Eds.), *Complement*. Springer-Verlag, Berlin, p. 379.
- Tsang, V.C.W., Hancock, K., Maddison, S.E., Beatti, A.L. and Moss, D.M. (1984) Demonstration of species specific and cross-reactive components of the adult microsomal antigens from *Schistosoma mansoni* and *S. japonicum* (MAMA and JAMA). *J. Immunol.* 132, 2607.
- Vallota, E.H. and Müller-Eberhard, H.J. (1973) Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. *J. Exp. Med.* 137, 1109.
- Webster, R.O., Hong, S.R., Johnson, Jr. R.B. and Henson, P.M. (1980) Biological effects of the human complement fragments C5a and C5a des arg on neutrophil function. *Immunopharmacology* 2, 201.
- Wetsel, R.A. and Kolb, W.P. (1983) Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with non-complement enzymes without release of polypeptide fragments. *J. Exp. Med.* 157, 2029.
- Wiggins, R.W., Giclas, P.C. and Henson, P.M. (1981) Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. *J. Exp. Med.* 153, 1391.